US 11,951,090 B2
Methods and pharmaceutical compositions for the treatment of FGFR3-related chondrodysplasias
Laurence Legeai-Mallet, Paris (FR); Antonio Segura Carretero, Granada (ES); and Maria De La Luz Cadiz Gurrea, Granada (ES)
Assigned to INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, Paris (FR); UNIVERSITÉ DE PARIS, Paris (FR); FONDATION IMAGINE, Paris (FR); ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS, Paris (FR); and UNIVERSIDAD DE GRANADA, Granada (ES)
Appl. No. 16/964,781
Filed by INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), Paris (FR); UNIVERSITE DE PARIS, Paris (FR); FONDATION IMAGINE, Paris (FR); ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), Paris (FR); and UNIVERSIDAD DE GRANADA, Grandada (ES)
PCT Filed Jan. 23, 2019, PCT No. PCT/EP2019/051622
§ 371(c)(1), (2) Date Jul. 24, 2020,
PCT Pub. No. WO2019/145356, PCT Pub. Date Aug. 1, 2019.
Claims priority of application No. 18305053 (EP), filed on Jan. 24, 2018.
Prior Publication US 2021/0052546 A1, Feb. 25, 2021
Int. Cl. A61K 31/353 (2006.01); A61P 19/00 (2006.01)
CPC A61K 31/353 (2013.01) [A61P 19/00 (2018.01)] 1 Claim
 
1. A method of treating a FGFR3-related chondrodysplasia in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a substantially pure (−)-epicatechin,
wherein the step of administering comprises administering to the patient a pharmaceutical composition comprising the substantially pure (−)-epicatechin as an active principle and at least one pharmaceutically acceptable excipient, and
wherein the pharmaceutical composition does not comprise a Theobroma cacao extract.